Generic Jynarque Availability
Last updated on Feb 8, 2024.
JYNARQUE (tolvaptan - tablet;oral)
Approval date: April 23, 2018
Strength(s): 15MG [RLD], 30MG [RLD], 45MG [RLD], 60MG [RLD], 90MG [RLD]
Has a generic version of Jynarque been approved?
No. There is currently no therapeutically equivalent version of Jynarque available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Jynarque. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Pharmaceutical solid preparation comprising benzazepines and production method thereof
Issued: February 2, 2021
Inventor(s): Nakagawa Shinsuke & Suzuki Kai & Mukai Tadashi
Assignee(s): OTSUKA PHARMACEUTICAL CO., LTD.
The subject invention provides a novel pharmaceutical solid preparation that has superior disintegration properties and excellent solubility, leading to sufficient absorbability of active ingredients through the gastrointestinal tract. The pharmaceutical solid preparation of the present invention comprises:
Patent expiration dates:
- April 7, 2030✓
- April 7, 2030
Process for preparing benzazepine compounds or salts thereof
Issued: August 6, 2013
Inventor(s): Torisawa Yasuhiro & Abe Kaoru & Muguruma Yasuaki & Fujita Shigekazu & Ogawa Hidenori & Utsumi Naoto & Miyake Masahiro
Assignee(s): Otsuka Pharmaceutical Co., Ltd.
This invention provides a process for preparing benzazepine compounds of the formula (1):
Patent expiration dates:
- September 1, 2026✓
- September 1, 2026
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 23, 2025 - INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
More about Jynarque (tolvaptan)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
|A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
|Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
|A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.